Global Leaders to Address Childhood Cancer and Sickle Cell Anemia at High-Level Meeting
Table of Contents
Despite significant advancements in medical science, a tragically high number of children continue to die from diseases that are preventable or treatable. A forthcoming high-level meeting (HLM4) aims to galvanize global action to improve access to care and accelerate progress in combating childhood cancer and sickle cell anemia,notably in low- and medium-income countries. This event will focus on ensuring that every child has a chance at survival and a better quality of life.
The Stark Reality of Childhood Illness
The statistics are sobering. According to the World Health Organization (WHO), less than 30% of children with cancer survive in countries with low to medium incomes. https://www.who.int/news-room/fact-sheets/detail/cancer-in-children Moreover, nearly half of all children with sickle cell anemia die before reaching the age of five. https://www.who.int/news-room/fact-sheets/detail/sickle-cell-disease Palliative care, crucial for alleviating suffering and enhancing quality of life for these children and their families, remains a relatively new concept in many regions, including parts of Europe.
HLM4: A Call to Action
The secondary event at HLM4 will bring together leading politicians and experts from around the world to accelerate measures aimed at improving access to care and ensuring no child is left behind in the fight against these non-communicable diseases.The meeting recognizes the urgent need for a child-pleasant, integrated, and sustainable approach to care for children facing rare and devastating illnesses.
Program Highlights
The HLM4 event will feature a compelling program designed to inspire action and foster collaboration:
Personal Stories: Powerful narratives from children and families directly impacted by childhood cancer and sickle cell anemia will highlight the human cost of these diseases and the importance of improved care.
Expert Insights: High-ranking representatives from the WHO, St. Jude Children’s Research Hospital, the government of Uzbekistan, and partner organizations will share their expertise and perspectives.
Podium 1: Advancing Childhood Cancer Care: This session will focus on sustaining progress in combating childhood cancer through the expansion of national programs, strengthening healthcare systems, and securing long-term investments. Podium 2: A Global Initiative for sickle cell Anemia: This discussion will facilitate the exchange of experiences between countries and the progress of a global roadmap to increase survival rates for children with sickle cell anemia.
Why This Matters: Understanding the Diseases
Childhood Cancer: Cancer is a leading cause of death from disease among children globally. While survival rates are high in developed countries, disparities exist, and access to diagnosis and treatment remains a significant challenge in many parts of the world. https://www.cancer.org/cancer/childhood-cancer/about-childhood-cancer.html
Sickle Cell Anemia: This inherited blood disorder causes red blood cells to become misshapen and break down,leading to chronic pain,organ damage,and increased susceptibility to infections. It disproportionately affects people of African, mediterranean, and South Asian descent. https://www.nhlbi.nih.gov/health/sickle-cell-disease
Key Takeaways
Childhood cancer and sickle cell anemia claim the lives of too many children, particularly in low- and medium-income countries.
HLM4 is a critical opportunity to mobilize global leaders and accelerate progress in improving access to care.
A child-friendly, integrated, and sustainable approach is essential for effective treatment and support.
Palliative care is a vital component of care, focusing on quality of life and relieving suffering.
join the Movement
The HLM4 event represents a pivotal moment in the fight against childhood cancer and sickle cell anemia. By tracking the event and contributing to the growing movement, individuals can help ensure that every child worldwide has the chance to survive and thrive.